A further boost for antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has come in the form of Priority Review designation and acceptance from the US regulator.
The drug’s developers, AstraZeneca (LSE: AZN) and Daiichi Sankyo (TYO: 4568), were granted the speedy review for a bid to widen the label to include people with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
Enhertu is the only HER2-directed medicine to demonstrate significant improvement in overall survival (OS), compared to chemo, in this later-line treatment setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze